Room to Run, the Race for a COVID-19 Antibody Drug, and the Most Underappreciated Risk

Room to Run, the Race for a COVID-19 Antibody Drug, and the Most Underappreciated Risk

  • Autor
  • Osa
      110
  • Avaldatud
      27. mai 2020
  • Kirjastaja
0 Hinnangud
0
Osa
110 of 1591
Kestus
46 min
Keel
inglise
Vorming
Kategooria
Majandus ja ettevõtlus

Another rally on Wall Street and two strategists both say there’s more room to run…where they’re finding opportunities.

The CEO of AbCellera joins to discuss the company’s partnership with Eli Lilly in the race for a COVID-19 antibody drug.

And two policy strategists weigh in one of the biggest and most underappreciated risks for the market right now.

Plus, a ‘cool’ trade for the summer.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.


Loe ja kuula

Astu lugude lõputusse maailma

  • Suurim valik eestikeelseid audio- ja e-raamatuid
  • Proovi tasuta
  • Loe ja kuula nii palju, kui soovid
  • Lihtne igal ajal tühistada
Proovi tasuta
Device Banner Block-copy 894x1036
Cover for Room to Run, the Race for a COVID-19 Antibody Drug, and the Most Underappreciated Risk

Muud podcastid, mis võivad sulle meeldida ...